Form 4: MANGOCEUTICALS Director Receives Equity Bonus

MANGOCEUTICALS, INC. Director Alex P. Hamilton was granted 100,000 shares of common stock as a discretionary bonus for services rendered.

Summary

• Director Alex P. Hamilton received a grant of 100,000 shares of MANGOCEUTICALS, INC. common stock.
• The shares were issued as a discretionary bonus in consideration for services rendered as a member of the Board of Directors.
• The grant was made under the registrant's Second Amended and Restated 2022 Equity Incentive Plan.
• Following this transaction, Mr. Hamilton beneficially owns a total of 126,667 shares of common stock.
• The transaction date was September 9, 2025, and the shares were acquired at a price of $0.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is generally a positive sign of management alignment and retention, but does not contain information that would significantly alter the company's fundamental outlook or immediate share price.

Positives

• The grant of 100,000 shares to a director indicates management's continued alignment with shareholder interests through equity compensation.
• Issuance under an existing equity incentive plan (Second Amended and Restated 2022 Equity Incentive Plan) suggests a structured and approved approach to executive compensation.
• The transaction is exempt under Rule 16b-3, indicating it is a routine compensation event and not subject to short-swing profit rules.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the reporting of a past transaction.

Management Comments

• Issued as a discretionary bonus in consideration for services rendered as a member of the Board of Directors.
• Issued under the registrant's Second Amended and Restated 2022 Equity Incentive Plan.

Industry Context

Equity grants to directors are a common practice across industries to align the interests of management with those of shareholders, encouraging long-term commitment and performance. This particular grant is a standard compensation event within the broader corporate governance framework.

Comparison to Industry Standards

• This is a standard equity compensation event for a director, common across publicly traded companies.
• Comparable companies frequently use equity incentive plans to reward and retain key personnel, with grants often tied to service or performance milestones.
• No specific comparable companies, projects, or results are mentioned in the filing to allow for a detailed comparison of the grant size or terms against industry benchmarks.

Corporate Governance

Related Party Transactions

• The equity grant to a director is a related party transaction, but it is a standard form of compensation and explicitly exempt under Rule 16b-3.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially encouraging long-term value creation. It represents a minor dilution from the issuance of new shares, which is typical for equity compensation plans.
• Employees: No direct impact on general employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice and generally viewed as a positive for aligning management incentives. However, it does not contain information significant enough to warrant a change in an existing investment thesis or a strong buy/sell recommendation. It's a neutral event in terms of immediate stock price impact, reinforcing a 'hold' position for existing investors.

Keywords

MANGOCEUTICALS, MGRX, Alex P. Hamilton, Director, Equity Grant, Stock Bonus, Form 4, Insider Ownership, Compensation